Generate QR code
Open Access
Subscription Access
Targeted delivery of protective substances using nano-sized carriers in ischemic-reperfusion kidney injury
Yu. V. Cheburkin,
E. A. Smirnov,
E. A. Murashko,
A. A. Kolobov,
A. B. Bondarenko,
N. O. Sitkov,
M. M. Galagudza https://doi.org/10.36485/1561-6274-2026-30-1-20-37
EDN: BOBKBX
Abstract
Acute ischemic-reperfusion injury (IRI) is the primary cause of acute kidney injury. Experimental studies have shown that the severity of IRI in renal tissue can be reduced through various pharmacological interventions. However, these data have not been successfully transferred into clinical practice, partly due to the suboptimal pharmacokinetic parameters of the drugs, their low bioavailability, and the occurrence of side effects with systemic administration. To address these issues, systems for the targeted delivery of drugs to the kidneys during IRI using nanoscale carriers have been developed in recent years. Binding to nanoparticles enables preferential accumulation of the active substance in the kidneys, followed by controlled release. For active targeted drug delivery to the kidneys during IRI, platforms containing specific guiding ligands and groups sensitive to local environmental conditions are being used. Most studies related to the development of targeted drug delivery systems for kidney tissue focus on antioxidants and anti-inflammatory agents. Improving targeted delivery systems is linked to actively targeting damaged kidney tissue, including using bio-like coatings on drug nanoparticles based on blood cell membranes.
Keywords
targeted delivery,
nanoparticles,
ischemia,
reperfusion,
kidney,
acute kidney injury,
nephroprotection
Supporting agencies: The research was performed at the expense of the state assignment of Almazov National Medical Research Center “Development of a method of targeted delivery based on nanoconjugates of cardio-targeting peptides” (reg. No.: 124021600063-1).
About the Authors
Yu. V. Cheburkin
Almazov National Medical Research Center
Russian Federation
Russian Federation
Yuri V. Cheburkin, MD, PhD, Head of the Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures
197341, Saint Petersburg, Akkuratova str., 2
Phone: (812) 7025168
E. A. Smirnov
Almazov National Medical Research Center
Russian Federation
Russian Federation
Evgeny A. Smirnov, Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Junior Researcher
197341, Saint Petersburg, Akkuratova str., 2
Phone: (812) 7025168
E. A. Murashko
Almazov National Medical Research Center; Institute of Medical Education
Russian Federation
Russian Federation
Ekaterina A. Murashko, PhD (Chem.), Head of the Research Laboratory of Metabolomic and Metabolic Profiling; Department of Chemistry, Assistant
197341, Saint Petersburg, Akkuratova str., 2
Phone: (812) 7025168
A. A. Kolobov
Research Institute of Hygiene, Occupational Pathology and Human Ecology
Russian Federation
Russian Federation
Alexey A. Kolobov, PhD (Biol.), Laboratory of Peptide Chemistry, Leading Researcher
188663, Leningrad region, Vsevolozhsky district, g.p. Kuzmolovskii, Zavodskaya str., 6/2, bldg. 93
Phone: (812) 7025168
A. B. Bondarenko
Almazov National Medical Research Center; Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Andrey B. Bondarenko, Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Junior Researcher; Department of Medical Biology, Senior Lecturer
197341, Saint Petersburg, Akkuratova str., 2; 194100, Saint Petersburg, Litovskaya str., 2. Saint Petersburg
Phone: (812) 7025168
N. O. Sitkov
Almazov National Medical Research Center; Saint Petersburg Electrotechnical University “LETI” named after V.I. Ulyanov (Lenin)
Russian Federation
Russian Federation
Nikita O. Sitkov, PhD (Tech.), Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Leading Researcher; Department of Micro- and Nanoelectronics, Associate Professor
197341, Saint Petersburg, Akkuratova str., 2; 197022, Russia, Saint Petersburg, Professor Popov str., 5, lit. F.
Phone: (812) 7025168
M. M. Galagudza
Almazov National Medical Research Center; Institute for Analytical Instrumentation; Institute of Medical Education
Russian Federation
Russian Federation
Professor Mikhail M. Galagudza, MD, PhD, DMedSci, Corresponding Member of the RAS, Director of the Institute of Experimental Medicine; Head of the Department of Pathological Physiology; Principal Researcher
197341, Saint Petersburg, Akkuratova str., 2; 198095, Saint Petersburg, Ivan Chernykh str., 31-33, lit. A
Phone: (812) 7025168
References
1. Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013;2013:479730. doi: 10.1155/2013/479730
2. Turgut F, Awad AS, Abdel-Rahman EM. Acute Kidney Injury: Medical Causes and Pathogenesis. J Clin Med 2023;12(1):375. doi: 10.3390/jcm12010375
3. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 2015;4(2):20–27. doi: 10.12861/jrip.2015.06
4. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376(1– 2):1–43. doi: 10.1007/s00210-007-0183-5
5. Liu D, Du Y, Jin FY et al. Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review. Mol Pharm 2021;18(9):3206–3222. doi: 10.1021/acs.molpharmaceut.1c00511
6. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121(11):4210–4221. doi: 10.1172/JCI45161
7. Lieberthal W, Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol 1998;275(5):F623–F631. doi: 10.1152/ajprenal.1998.275.5.F623
8. Kim MJ, Oh CJ, Hong CW, Jeon JH. Comprehensive overview of the role of mitochondrial dysfunction in the pathogenesis of acute kidney ischemia-reperfusion injury: a narrative review. J Yeungnam Med Sci 2024;41(2):61–73. doi: 10.12701/jyms.2023.01347
9. Li C, Yu Y, Zhu S et al. The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives. Cell Death Discov 2024;10(1):216. doi: 10.1038/s41420-024-01979-4
10. DeWolf SE, Kasimsetty SG, Hawkes AA et al. DAMPs Released from Injured Renal Tubular Epithelial Cells Activate Innate Immune Signals in Healthy Renal Tubular Epithelial Cells. Transplantation 2022;106(8):1589–1599. doi: 10.1097/TP.0000000000004038
11. Su X, Liu B, Wang S et al. NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation. Transpl Immunol 2022;75:101718. doi: 10.1016/j.trim.2022.101718
12. Wahl P, Schoop R, Bilic G et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002;13(6):1517–1526. doi: 10.1097/01.asn.0000017901.77985f
13. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387–6392.
14. Gatto MS, Johnson MP, Najahi-Missaoui W. Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges. Life 2024;14(6):672. doi: 10.3390/life14060672
15. Skwarczynski M, Bashiri S, Yuan Y et al. Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents. Antibiotics 2022;11(3):412. doi: 10.3390/antibiotics11030412
16. Korolev D, Shumilo M, Shulmeyster G et al. Hemolytic Activity, Cytotoxicity, and Antimicrobial Effects of Silver Nanoparticles Conjugated with Lincomycin or Cefazolin. Int J Mol Sci 2022;23(22):13709. doi: 10.3390/ijms232213709
17. Galagudza M, Korolev D, Postnov V et al. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine 2012;7:1671–1678. doi: 10.2147/IJN.S29511
18. Ren JX, Ma HY, Yin WJ et al. Emerging Targeted Delivery Strategies of Nanosystems for Ischemic Stroke Treatment. Int J Nanomedicine 2025;20:8143–8171. doi: 10.2147/IJN.S519328
19. Roointan A, Xu R, Corrie S et al. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions. J Am Soc Nephrol 2025;36(3):500–518. doi: 10.1681/ASN.0000000608
20. Yan S, Na J, Liu X, Wu P. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics 2024;16(2):248. doi: 10.3390/pharmaceutics16020248
21. Xian X, Ren Q, Du H et al. Advances in Homing Peptide Targeted Therapies. Int J Pept Res Ther 2025;31:36. doi: 10.1007/s10989-024-10682-y
22. Zielonka J, Joseph J, Sikora A et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev 2017;117(15):10043–10120. doi: 10.1021/acs.chemrev.7b00042
23. Zhang S, Zhang X, Gao H et al. Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment. Pharmaceutics 2024;16(4):531. doi: 10.3390/pharmaceutics16040531
24. Liu Z, Liu X, Yang Q et al. Neutrophil membrane-enveloped nanoparticles for the amelioration of renal ischemia-reperfusion injury in mice. Acta Biomater 2020;104:158–166. doi: 10.1016/j.actbio.2020.01.018
25. Wang X, Bai R. Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases. Drug Deliv 2023;30(1):2256495. doi: 10.1080/10717544.2023.2256495
26. Li H, Zhang Y, Shu H et al. Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies. Int J Pharm 2022;613:121412. doi: 10.1016/j.ijpharm.2021.121412
27. Kong Y, Chen X, Liu F et al. Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression. Adv Mater 2024;36(30):e2310731. doi: 10.1002/adma.202310731
28. Hauser PV, Chang HM, Yanagawa N, Hamon M. Nanotechnology, Nanomedicine, and the Kidney. Appl Sci 2021;11(16):7187. doi: 10.3390/app11167187
29. Wu L, Chen M, Mao H et al. Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes. Int J Mol Med 2017;39(4):851–860. doi: 10.3892/ijmm.2017.2902
30. Wang J, Poon C, Chin D et al. Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. Nano Res 2018;11:5584–5595. doi: 10.1007/s12274-018-2100-2
31. Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 2012;109(8):3137– 3142. doi: 10.1073/pnas.1200718109
32. Yang J, Zhang R, Wang F et al. Red blood cell membranecamouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery. J Drug Deliv Sci Tech 2023;86:104693. doi: 10.1016/j.jddst.2023.104693
33. Lee TY, Lu HH, Cheng HT et al. Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis. J Control Release 2023;354:417–428. doi: 10.1016/j.jconrel.2022.12.059
34. Williams RM, Shah J, Tian HS et al. Selective Nanoparticle Targeting of the Renal Tubules. Hypertension 2018;71(1):87–94. doi: 10.1161/HYPERTENSIONAHA.117.09843
35. Wang J, Masehi-Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci 2017;5(8):1450–1459. doi: 10.1039/c7bm00271h
36. Wischnjow A, Sarko D, Janzer M et al. Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. Bioconjug Chem 2016;27(4):1050–1057. doi: 10.1021/acs.bioconjchem.6b00057
37. Yoshitomi T, Hirayama A, Nagasaki Y. The ROS scavenging and renal protective effects of pH-responsive nitroxide radicalcontaining nanoparticles. Biomaterials 2011;32(31):8021–8028. doi: 10.1016/j.biomaterials.2011.07.014
38. Xie D, Xu Y, Jing W et al. Berberine nanoparticles protects tubular epithelial cells from renal ischemia-reperfusion injury. Oncotarget 2017;8(15):24154–24162. doi: 10.18632/oncotarget.16530
39. Yan J, Wang Y, Zhang J et al. Rapidly Blocking the Calcium Overload/ROS Production Feedback Loop to Alleviate Acute Kidney Injury via Microenvironment-Responsive BAPTA-AM/BAC Co-Delivery Nanosystem. Small 2023;19(17):e2206936. doi: 10.1002/smll.202206936
40. Zheng Z, Deng G, Qi C et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress. Int J Nanomedicine 2018;14:215–229. doi: 10.2147/IJN.S184804
41. Li J, Duan Q, Wei X et al. Kidney-Targeted Nanoparticles Loaded with the Natural Antioxidant Rosmarinic Acid for Acute Kidney Injury Treatment. Small 2022;18(48):e2204388. doi: 10.1002/smll.202204388
42. Hou Y, Lin S, Xia J et al. Alleviation of ischemia-reperfusion induced renal injury by chemically modified SOD2 mRNA delivered via lipid nanoparticles. Mol Ther Nucleic Acids 2023;34:102067. doi: 10.1016/j.omtn.2023.102067
43. Zhang J, Ren X, Nie Z et al. Dual-responsive renal injury cells targeting nanoparticles for vitamin E delivery to treat ischemia reperfusion-induced acute kidney injury. J Nanobiotechnology 2024;22(1):626. doi: 10.1186/s12951-024-02894-7
44. Zuo Z, Luo M, Liu Z et al. Selenium nanoparticles alleviate renal ischemia/reperfusion injury by inhibiting ferritinophagy via the XBP1/NCOA4 pathway. Cell Commun Signal 2024;22(1):376. doi: 10.1186/s12964-024-01751-2
45. Zhou L, Tang S, Li F et al. Ceria nanoparticles prophylactic used for renal ischemia-reperfusion injury treatment by attenuating oxidative stress and inflammatory response. Biomaterials 2022;287:121686. doi: 10.1016/j.biomaterials.2022.121686
46. Saleh H, Salama M, Hussein RM. Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia-reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway. Environ Sci Pollut Res Int 2022;29(51):77884–77907. doi: 10.1007/s11356-022-21235-5
47. Huang ZW, Shi Y, Zhai YY et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury. J Control Release 2021;334:275–289. doi: 10.1016/j.jconrel.2021.04.033
48. Qin S, Wu B, Gong T et al. Targeted delivery via albumin corona nanocomplex to renal tubules to alleviate acute kidney injury. J Control Release 2022;349:401–412. doi: 10.1016/j.jconrel.2022.07.013
49. Zhang J, Xie H, Wang T et al. Epicatechin-assembled nanoparticles against renal ischemia/reperfusion injury. J Mater Chem B 2022;10(36):6965–6973. doi: 10.1039/d2tb01301k
50. Wang N, Xue X, Zhang Z et al. Curcumin-loaded nanoparticles for renal ischemia-reperfusion injuries: Triple-play of redox homeostasis accommodation, lipid metabolism regulation, and nuclear magnetic tracing. Mater Today Bio 2025;33:101986. doi: 10.1016/j.mtbio.2025.101986
51. Han SJ, Williams RM, D’Agati V et al. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int 2020;98(1):76–87. doi: 10.1016/j.kint.2020.01.036
52. Shen Y, Yang F, Wu F et al. STING antagonist-loaded renal tubule epithelial cell-mimicking nanoparticles ameliorate acute kidney injury by orchestrating innate and adaptive immunity. Nano Today 2024;55:102209. doi: 10.1016/j.nantod.2024.102209
53. Kim S, Jo H, Lee S et al. Targeted echogenic and antiinflammatory polymeric prodrug nanoparticles for the management of renal ischemia/reperfusion injury. J Control Release 2023;363:574–584. doi: 10.1016/j.jconrel.2023.10.004
54. Shin H, Jeong S, Lee Y et al. H2O2-Activatable Antioxidant Polymeric Prodrug Nanoparticles for the Prevention of Renal Ischemia/Reperfusion Injury. Biomacromolecules 2022;23(9):3810– 3821. doi: 10.1021/acs.biomac.2c00669
55. Guo L, Wang H, Liu X et al. Prolonged Retention of Albumin Nanoparticles Alleviates Renal Ischemia-Reperfusion Injury through Targeted Pyroptosis. ACS Appl Mater Interfaces 2024;16(44):59921–59933. doi: 10.1021/acsami.4c13481
56. Xu L, Xing Z, Yuan J et al. Ultrasmall Nanoparticles Regulate Immune Microenvironment by Activating IL-33/ST2 to Alleviate Renal Ischemia-Reperfusion Injury. Adv Healthc Mater 2024;13(13):e2303276. doi: 10.1002/adhm.202303276
57. Karimi Z, Asadi K, Ghahramani P, Gholami A. Trinitroglycerine-loaded chitosan nanoparticles attenuate renal ischemia-reperfusion injury by modulating oxidative stress. Sci Rep 2024;14(1):32112. doi: 10.1038/s41598-024-83886-3
58. Chen J, Vemuri C, Palekar RU et al. Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury. Am J Physiol Renal Physiol 2015;308(7):F765–F773. doi: 10.1152/ajprenal.00457.2014
59. Vallorz EL, Janda J, Mansour HM, Schnellmann RG. Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney Int 2022;102(5):1073–1089. doi: 10.1016/j.kint.2022.05.032
60. Xie D, Wang J, Hu G et al. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury. J Pharmacol Exp Ther 2021;378(3):235–243. doi: 10.1124/jpet.121.000667
61. Jiang W, Hou X, Qi Y et al. pH-Activatable Pre-Nanozyme Mediated H2S Delivery for Endo-Exogenous Regulation of Oxidative Stress in Acute Kidney Injury. Adv Sci 2024;11(18):e2303901. doi: 10.1002/advs.202303901
62. Embaby EM, Saleh RM, Marghani BH et al. The combined effect of zinc oxide nanoparticles and milrinone on acute renal ischemia/reperfusion injury in rats: Potential underlying mechanisms. Life Sci 2023;323:121435. doi: 10.1016/j.lfs.2023.121435
63. Xu M, Zhao M, Zheng D. Effect of IGF-1C domain-modified nanoparticles on renal ischemia-reperfusion injury in mice. Ren Fail 2022;44(1):1376–1387. doi: 10.1080/0886022X.2022.2098773
64. Zhang R, Zhang X, Zhu X et al. Nanoparticles transfected with plasmid-encoded lncRNA-OIP5-AS1 inhibit renal ischemiareperfusion injury in mice via the miR-410-3p/Nrf2 axis. Ren Fail 2024;46(1):2319327. doi: 10.1080/0886022X.2024.2319327
65. Hou Y, Xin Y, Liu S et al. A biocompatible nanoparticlebased approach to inhibiting renal ischemia reperfusion injury in mice by blocking thrombospondin-1 activity. Am J Transplant 2022;22(9):2246–2253. doi: 10.1111/ajt.17052
Review
For citations:
Cheburkin Yu.V., Smirnov E.A., Murashko E.A., Kolobov A.A., Bondarenko A.B., Sitkov N.O., Galagudza M.M. Targeted delivery of protective substances using nano-sized carriers in ischemic-reperfusion kidney injury. Nephrology (Saint-Petersburg). 2026;30(1):20-37. (In Russ.) https://doi.org/10.36485/1561-6274-2026-30-1-20-37. EDN: BOBKBX
Views:
216
JATS XML
Email this article 